基于lentiviral 载体的T细胞疫苗对抗寨卡病毒和黄热病病毒
Pierre Authié1, Philippe Souque1, Fanny Moncoq1
1Pasteur-TheraVectys Joint Laboratory, Institut Pasteur, Université Paris Cité, Paris F-75015, France.
Vaccine
|August 3, 2025
概括
新的lentiviral载体提供了一个有前途的寨卡和黄热病疫苗方法. 这些基于T细胞的疫苗诱导保护性免疫力,而不会通过抗体增强疾病.
科学领域:
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
- 疫苗学 疫苗学 疫苗学
背景情况:
- 寨卡病毒和黄热病病毒是引起人类重大疾病的黄病毒,主要在热带地区.
- 新兴的寨卡病毒和重新出现的黄热病病毒构成了持续的公共卫生威胁.
- 抗体依赖增强 (ADE) 对传统针对相关黄病毒的疫苗构成风险.
研究的目的:
- 开发和评估基于T细胞的新型疫苗策略,以对抗寨卡病毒和黄热病病毒.
- 探索表达寨卡病毒和黄热病病毒T细胞表位体的lentiviral载体的潜力.
- 在相关动物模型中评估这些载体的免疫性和保护功效.
主要方法:
- 病毒载体被设计为表达来自寨卡病毒和黄热病病毒的T细胞表位区域.
- 通过测量T细胞反应来评估免疫性.
- 保护性疗效在与寨卡病毒或黄热病病毒挑战的干扰素α/β受体淘汰 (ifnar-/-) 鼠标模型中进行了评估.
- 关键结局包括病毒病,器官中的病毒载量,体重减轻和器官病理.
主要成果:
- 病毒载体成功诱导T细胞对寨卡病毒和黄热病病毒的反应.
- 这些反应发生在没有感染增强抗体的证据的情况下.
- 接种疫苗的小鼠对两种病毒都有显著的保护.
- 保护的特点是病毒载荷减少,体重减轻最小,器官病理减弱.
结论:
- 使用lentiviral载体的基于T细胞的疫苗是对寨卡病毒和黄热病的可行策略.
- 这种方法避免了与其他疫苗类型相关的抗体依赖增强的风险.
- 这些发现支持进一步开发针对黄病毒性疾病的T细胞表位基疫苗.
相关概念视频
Cytotoxic T Cells-mediated Immune Response
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immune Response Against Viral Pathogens
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Yellow Fever
Yellow fever is a viral hemorrhagic disease caused by the yellow fever virus (YFV), a member of the Flaviviridae family. It is transmitted primarily by Aedes and Haemagogus mosquitoes in tropical and subtropical regions of Africa and South America. After transmission through a mosquito bite, the virus initially replicates in skin-resident immune cells such as dendritic cells and macrophages. These cells then migrate to the lymph nodes, where viral replication increases, eventually leading to...
Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...


